Do not stop or change your medication without speaking to a pharmacist or healthcare professional.
Anticipated Shortage

SANDOZ AFATINIB

SANDOZ CANADA INCORPORATED

This is a national manufacturer shortage report. It does not confirm whether the product is unavailable at your local pharmacy — call ahead or ask your pharmacist.

Quick answers

Is there a shortage of SANDOZ AFATINIB in Canada?

A shortage of SANDOZ AFATINIB 40MG is expected: the manufacturer reported it to Health Canada as an anticipated shortage (last updated September 14, 2026), but it has not started yet.

Why is SANDOZ AFATINIB not available?

The reason the manufacturer reported: Shortage of an active ingredient.

When will SANDOZ AFATINIB be available again?

The manufacturer's estimated resolution date is November 6, 2026. This is an estimate and can change; follow this page to get an email when the status changes.

Can I still get this?Possibly — same-ingredient product records found
StatusAnticipated Shortage
Same-ingredient products on file2 products
Expected resolution~39 days remaining (estimate)
Affected strength40MG
Last updated2026-09-14

Other Products Containing the Same Active Ingredient

These are other Health Canada-approved human drug products containing the same active ingredient, not currently reported in shortage. Strength, dosage form, and route can still differ — ask your pharmacist whether any of these are appropriate for you. This isn't a guarantee of current stock.

Other Products

TEVA-AFATINIB

TEVA CANADA LIMITED

30MG · DIN 02514605

Different strengthSame dosage formSame routeNo current shortage

MAR-AFATINIB

MARCAN PHARMACEUTICALS INC

30MG · DIN 02517027

Different strengthSame dosage formSame routeNo current shortage

What this means

Does this mean my pharmacy is already out of stock?

No — this shortage hasn't started yet. It's an early warning that supply may become tight, based on information from the manufacturer.

What should I do?

No action is needed yet. It's worth asking your pharmacist at your next refill whether they expect any disruption for this product.

DIN

02512793

Strength

40MG

Dosage Form

TABLET

Route

ORAL

Active Ingredient

AFATINIB

See all AFATINIB products →

Shortage Timeline

Approximate — based on the dates HPSC reports were last updated, not confirmed onset or resolution dates. Gaps between bars are periods with no shortage on file.

Active/anticipated Resolved

Shortage History